Thursday, January 27, 2022   fundraising

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

[01/27/2022, Nantong] Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led...

News and events

Wednesday, February 10, 2021   News

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

[2/11/2021, Nantong] Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million USD (¥110 million) Series A financing round led by Hillhouse Venture Capital with participation from CCB Healthcare Growth Fund, Boyi Capital, and...

CB Insights, RNA biotech companies, China

Tuesday, May 19, 2020   News

CB Insights lists Ractigen as one of the Top RNA biotech companies in China

[May 19th, 2020] Today, CB Insights China published, for the first time, a top list of RNA biotech companies in China and Ractigen Therapeutics, as the only company developing RNAa therapeutics, is listed as top 3.

CB Insights is a world-renowned venture capital analysis...

Wednesday, July 11, 2018   News

Delegation from Nantong University Medical School visits Ractigen

[July 11, 2018] Today, a 5-member delegation, led by the dean Professor Fei Sun, from Nantong University Medical School paid a visit to Ractigen and Rudong Life and Health Industry Park. After touring the company building and getting a taste of the overall work environment, the group retired to...

saRNA, rcc, vhl, RNAa

Wednesday, February 7, 2018   News

Scientists from Ractigen and KRIBB publish new study on saRNA-guided activation of VHL gene in renal cell carcinoma

[Feb. 6th, 2018] Today, an article entitled "Small activating RNA induced expression of VHL gene in renal cell carcinoma" and co-authored by scientists from Ractigen and Korea Research Institute of Bioscience and Biotechnology (KRIBB) appeared online on the website of the International Journal...

Wednesday, October 11, 2017   News

Ractigen Therapeutics CSO Dr. Robert Place delivers a keynote speech at the 6th RNAi China conference

The 6th RNAi China conference was held on October 10th and 11th at Kunshan as expected. A host of leading experts in the fields of oligonucleotide research and drug development from both academia and industry including Ractigen Therapeutics’s CEO Dr. Long-Cheng Li participated in this conference...

Saturday, July 15, 2017   Events

Delivery of p21 saRNA into rectum shows antitumor efficacy in a preclinical study

A recent study published in Biomaterials's ahead of print issue of June reported in vivo efficacy of p21 saRNA delivered intrarectally to mice bearing orthotopic colorectal cancer. According to a news story published on the website of the Institute of Materia Medica (IMM), Chinese...